scispace - formally typeset
C

Christopher L. Wolfgang

Researcher at New York University

Publications -  625
Citations -  54429

Christopher L. Wolfgang is an academic researcher from New York University. The author has contributed to research in topics: Pancreatic cancer & Medicine. The author has an hindex of 94, co-authored 557 publications receiving 42133 citations. Previous affiliations of Christopher L. Wolfgang include University of California, San Francisco & Vanderbilt University.

Papers
More filters
Journal ArticleDOI

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Chetan Bettegowda, +69 more
TL;DR: The ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types was evaluated and suggested that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes.
Journal ArticleDOI

Genomic analyses identify molecular subtypes of pancreatic cancer

Peter Bailey, +128 more
- 03 Mar 2016 - 
TL;DR: Detailed genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing.
Journal ArticleDOI

The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula : 11 Years After

TL;DR: This new definition and grading system of postoperative pancreatic Fistula should lead to a more universally consistent evaluation of operative outcomes after pancreatic operation and will allow for a better comparison of techniques used to mitigate the rate and clinical impact of a pancreatic fistula.
Journal ArticleDOI

Whole genomes redefine the mutational landscape of pancreatic cancer.

Nicola Waddell, +88 more
- 26 Feb 2015 - 
TL;DR: Genomic instability co-segregated with inactivation of DNA maintenance genes (BRCA1, BRCA2 or PALB2) and a mutational signature of DNA damage repair deficiency, and 4 of 5 individuals with these measures of defective DNA maintenance responded to platinum therapy.